ImmunityBio, Inc.
8.22USD
-0.0900 (-1.08%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on IBRX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.05▲ | -$0.07 | 1 | 0 |
| Next quarter | -$0.04▲ | -$0.05 | 1 | 0 |
| Current year | -$0.92▼ | $0 | 1 | 1 |
| Next year | -$0.07▼ | $0.06 | 1 | 0 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.08 | -$0.22 | -0.14 (-175.0%) |
| 2026-03-31 | -$0.07 | -$0.08 | -0.01 (-20.0%) |
| 2025-12-31 | -$0.1 | -$0.06 | +0.04 (+37.9%) |
| 2025-09-30 | -$0.1 | -$0.07 | +0.03 (+30.0%) |
73 ratings from 6 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Jefferies | Maintained | Buy | $12 $14 | Oct 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $15 | Oct 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $15 | Jun 2, 2026 |
| BTIG | Reiterated | Buy | $12 | May 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $15 | May 20, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | May 5, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Apr 21, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Apr 8, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Mar 26, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Mar 23, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Mar 17, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Mar 9, 2026 |
| Piper Sandler | Reiterated | Overweight | $7 $12 | Mar 4, 2026 |
| D. Boral Capital | Maintained | Buy | $23 | Feb 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10 $15 | Feb 23, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Feb 19, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Feb 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8 $10 | Jan 26, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Jan 23, 2026 |
| BTIG | Maintained | Buy | $6 $9 | Jan 23, 2026 |
| Piper Sandler | Maintained | Overweight | $5 $7 | Jan 20, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Jan 20, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Jan 16, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Jan 13, 2026 |
| D. Boral Capital | Maintained | Buy | $24 | Dec 16, 2025 |
40 filings from 7 insiders · 12 buy / 7 sell over 6m
Officers and directors of IBRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SIMON BARRY J. M.D.Director | Sell | 25.0k | $10.75 | $269k | Oct 5, 2026 |
| COHEN CHERYL LDirector | Sell | 81.1k | $10.50 | $851k | Oct 2, 2026 |
| COHEN CHERYL LDirector | Exercise | 56.0k | $2.98 | $167k | Oct 2, 2026 |
| COHEN CHERYL LDirector | Sell | 131.2k | $9.50 | $1.25M | Jul 2, 2026 |
| COHEN CHERYL LDirector | Exercise | 56.0k | $2.98 | $167k | Jul 2, 2026 |
| SELECKY CHRISTOBEL E.Director | Sell | 159.5k | $9.02 | $1.44M | Jul 1, 2026 |
| SELECKY CHRISTOBEL E.Director | Exercise | 159.5k | $2.98 | $476k | Jul 1, 2026 |
| SELECKY CHRISTOBEL E.Director | Sell | 96.7k | $9.00 | $871k | Jun 30, 2026 |
| SELECKY CHRISTOBEL E.Director | Exercise | 96.7k | $2.84 | $284k | Jun 30, 2026 |
| SIMON BARRY J. M.D.Director | Sell | 25.0k | $7.88 | $197k | Jun 24, 2026 |
| SIMON BARRY J. M.D.Director | Sell | 23.0k | $7.18 | $165k | Jun 4, 2026 |
| SOON-SHIONG PATRICKOfficer, Director and Beneficial Owner | Exerciseindirect | 4.61M | $5.43 | $25.00M | Mar 31, 2026 |
| SIMON BARRY J. M.D.Director | Sell | 75.0k | $12.01 | $901k | Feb 24, 2026 |
| SIMON BARRY J. M.D.Director | Sell | 175.0k | $9.25 | $1.78M | Feb 23, 2026 |
| SELECKY CHRISTOBEL E.Director | Sell | 25.0k | $10.00 | $250k | Feb 23, 2026 |
| SELECKY CHRISTOBEL E.Director | Exercise | 25.0k | $2.98 | $75k | Feb 23, 2026 |
| SOON-SHIONG PATRICKOfficer, Director and Beneficial Owner | Other | 114.3k | — | — | Feb 20, 2026 |
| SACHS DAVID CChief Financial Officer | Other | 40.6k | — | — | Feb 20, 2026 |
| ADCOCK RICHARDChief Executive Officer | Other | 152.4k | — | — | Feb 20, 2026 |
| SIMON BARRY J. M.D.Director | Other | 15.2k | — | — | Feb 20, 2026 |
No analyst notes on IBRX yet.
Members whose judged calls on IBRX have played out most reliably.
No settled calls on IBRX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
4 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 3 | 0 | 0 | 0 | Buy1.75 |
| 1 mo ago | 1 | 3 | 0 | 0 | 0 | Buy1.75 |
| 2 mo ago | 1 | 3 | 0 | 0 | 0 | Buy1.75 |
| 3 mo ago | 1 | 3 | 0 | 0 | 0 | Buy1.75 |